1
Disclosures
Feb 4, 2026 — Mar 9, 2026
Date Range
PRIME
Market Segment

Disclosures

DateTypeHeadlinePDF
Mar 9 Other Astellas Pharma's Phase III PASHA Trial for XOSPATA Fails Primary Endpoint PDF

Disclosure Types

Other: 1